VERTEX PHARMACEUTICALS INCORPORATED;VERTEX PHARMACEUTICALS INC.
发明人:
BINCH, HAYLEY,GROOTENHUIS, PETER D.J.,HADIDA RUAH, SARA S.,ZHOU, JINGLAN,HAZLEWOOD, ANNA,FANNING, LEV T.D.
申请号：
ES08830930
公开号：
ES2445442T3
申请日:
2008.09.15
申请国别(地区):
ES
年份:
2014
代理人:
摘要：
A compound of formula I: ** Formula ** or a pharmaceutically acceptable salt or tautomer thereof, wherein: R3 is -ZAR5, in which each ZA is, independently, a linear aliphatic chain or linkage or C1-6 branched unsubstituted, and R5 is an aryl or a heteroaryl, any of which is optionally substituted, or R5 is a 3- to 6-membered cycloaliphatic group substituted with 1 to 2 selected groups, independently, from optionally substituted aryl and optionally substituted heteroaryl； each R1 is, independently, -X-RA, in which each X is, independently, an optionally substituted C1-6 linear or branched aliphatic chain or link, in which up to two X-carbon units are optionally replaced and independently with -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2- -OCO-, -NR'CO2-, -O-, -NR'CONR'- , -OCONR'-, -NR'NR ', -NR'NR'CO-, -NR'CO-, -S-, -SO, -SO2-, -NR'-, -SO2NR' -, - NR ' SO2- or -NR'SO2NR'-； RA is, independently, R ', halo, -NO2, -CN, -CF3 or -OCF3； each R 'is hydrogen or an optionally substituted group selected from a saturated C1-8 monocyclic aliphatic ring, partially unsaturated or completely unsaturated with 3 to 8 members having 0 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur, or a saturated, partially unsaturated or completely unsaturated bicyclic ring system of 8 to 12 members having 0 to 5 heteroatoms independently selected from nitrogen, oxygen or sulfur； or two occurrences of R are taken together with the atom (s) to which they are / are attached to form a saturated, partially unsaturated or completely unsaturated ring of 3 to 12 optionally substituted having 0 to 4 heteroatoms independently selected from entitrogen, oxygen or sulfur； R2 is hydrogen； R4 is hydrogen or a C1-6 aliphatic group optionally substituted with -X-RA； and each Z1 or Z2 is, independently, -CH-, -CR1- or N, and at least one of Z1 or Z2 is N.Un compuesto de fórmula I:**Fórmula** o una sal o un tautómero farmacéuticamente aceptables del mismo, en la que: R3 es -ZAR5, en el que c
